Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Jun;19(6):e70089.
doi: 10.1111/crj.70089.

The Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) as Predictive Tool in Hospitalised Patients With Community-Acquired Pneumonia (CAP)

Lisa Hessels  1 , Ruud Duijkers  1   2 , Marianne Schoorl  3 , Lotte Terpstra  1 , Willemien Thijs  1 , Wim Boersma  1
Affiliations
Randomized Controlled Trial

The Value of Soluble Urokinase Plasminogen Activator Receptor (suPAR) as Predictive Tool in Hospitalised Patients With Community-Acquired Pneumonia (CAP)

Lisa Hessels et al. Clin Respir J. 2025 Jun.

Abstract

Background: Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker elevated in severely ill patients, but its prognostic value in community-acquired pneumonia (CAP) remains unclear. This study aimed to evaluate suPAR's prognostic role for CAP severity compared to other biomarkers and severity scores.

Methods: A total of 204 hospitalised CAP patients were enrolled. C-reactive protein (CRP), procalcitonin (PCT), suPAR, CURB-65 and Pneumonia Severity Index (PSI) scores were measured at admission, and patients were followed for 365 days. The primary outcome was the relationship between suPAR levels and CAP severity based on IDSA/ATS guidelines. Secondary outcomes included time to clinical stability (TTCS), length of stay (LOS) and mortality.

Results: Among 204 patients, 174 (85%) had non-severe and 30 (15%) had severe CAP. SuPAR levels were not associated with severe CAP (OR 1.03, 95% CI 0.88-1.21; AUC 0.53). Unlike the PSI and CURB-65 scores, suPAR did not correlate with TTCS (HR PSI 0.80, HR CURB-65 0.86), though all three markers were correlated to LOS (AUC suPAR 0.61). Only suPAR was significantly associated with 30-day mortality (HR 1.51, AUC 0.68).

Conclusions: The prognostic value of suPAR for CAP severity is low, and it does not provide additional prognostic benefit over the CURB-65 or PSI scores in predicting CAP severity. While it has moderate predictive ability for 30-day mortality, its utility for predicting LOS or TTCS is low.

Trial registration: ClinicalTrials.gov identifier: NCT01964495.

Keywords: biomarkers; pneumonia; prognosis; severity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Correlation of C‐reactive protein (CRP), procalcitonin (PCT) and soluble urokinase‐type plasminogen activator receptor (suPAR) with the Pneumonia Severity Index (PSI) and CURB‐65 score.
FIGURE 2
FIGURE 2
Receiver‐operating curve (ROC) of discriminating severe versus non‐severe CAP.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Bjerre L. M., Verheij T. J., and Kochen M. M., “Antibiotics for Community Acquired Pneumonia in Adult Outpatients,” Cochrane Database of Systematic Reviews no. 2 (2004): CD002109. - PubMed
    1. Oosterheert J. J., Bonten M. J., Hak E., Lammers J. W., Schneider M. M., and Hoepelman I. M., “The Increase in Pneumonia‐Related Morbidity and Mortality Among Adults in the Netherlands and Possible Explanations for It,” Nederlands Tijdschrift Voor Geneeskunde 148 (2004): 1765–1769. - PubMed
    1. Niederman M. S., Mandell L. A., Anzueto A., et al., “Guidelines for the Management of Adults With Community‐Acquired Pneumonia. Diagnosis, Assessment of Severity, Antimicrobial Therapy, and Prevention,” American Journal of Respiratory and Critical Care Medicine 163, no. 7 (2001): 1730–1754, 10.1164/ajrccm.163.7.at1010. - DOI - PubMed
    1. Mortensen E. M., Coley C. M., Singer D. E., et al., “Causes of Death for Patients With Community‐Acquired Pneumonia: Results From the Pneumonia Patient Outcomes Research Team Cohort Study,” Archives of Internal Medicine 162, no. 9 (2002): 1059–1064, 10.1001/archinte.162.9.1059. - DOI - PubMed
    1. Marti C., Garin N., Grosgurin O., et al., “Prediction of Severe Community‐Acquired Pneumonia: A Systematic Review and Meta‐Analysis,” Critical Care 16, no. 4 (2012): R141. - PMC - PubMed

Publication types

MeSH terms

Associated data

Grants and funding